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Boston, Massachusetts, USAThe kallikrein-kinin system has been shown to be involved
in the development of diabetic nephropathy, but speciﬁc
mechanisms are not fully understood. Here, we determined
the renal-protective role of exogenous pancreatic kallikrein
in diabetic mice and studied potential mechanisms in
db/db type 2 diabetic and streptozotocin-induced type 1
diabetic mice. After the onset of diabetes, mice were
treated with either pancreatic kallikrein (db/dbDkallikrein,
streptozotocinDkallikrein) or saline (db/dbDsaline,
streptozotocinDsaline) for 16 weeks, while another
group of streptozotocin-induced diabetic mice received
the same treatment after onset of albuminuria
(streptozotocin’Dkallikrein, streptozotocin’Dsaline). Db/m
littermates or wild type mice were used as non-diabetic
controls. Pancreatic kallikrein had no effects on body
weight, blood glucose and blood pressure, but signiﬁcantly
reduced albuminuria among all three groups. Pathological
analysis showed that exogenous kallikrein decreased
the thickness of the glomerular basement membrane,
protected against the effacement of foot process, the
loss of endothelial fenestrae, and prevented the loss of
podocytes in diabetic mice. Renal ﬁbrosis, inﬂammation
and oxidative stress were reduced in kallikrein-treated
mice compared to diabetic controls. The expression of
kininogen1, tissue kallikrein, kinin B1 and B2 receptors
were all increased in the kallikrein-treated compared to
saline-treated mice. Thus, exogenous pancreatic kallikrein
both prevented and ameliorated diabetic nephropathy,
which may be mediated by activating the kallikrein-kinin
system.
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D iabetic nephropathy (DN), a major cause of end-stagerenal disease, has become a worldwide public healthissue.1,2 Several clinical studies provided convincing
evidence that angiotensin-converting enzyme inhibitors,
which inhibit angiotensin II formation and bradykinin degra-
dation, had blood pressure–independent beneﬁcial effects on
DN in both types 1 and 2 diabetes.3–6 This highlighted that
the kallikrein-kinin system (KKS) was also involved in DN.
In an Akita diabetic mouse model lacking both types I and
II bradykinin receptors (B1R and B2R, respectively), Kakoki
et al.7 found that these mice displayed detrimental pheno-
types, including urinary albumin excretion, glomerulosclero-
sis, and glomerular basement membrane thickening, In
addition, overexpressing tissue kallikrein in mouse models
ameliorated hypertension, insulin resistance, and DN.8–10
These studies suggested that KKS might be a useful target
for the treatment of DN.
Tissue kallikrein is a serine protease that converts kini-
nogen to the peptide hormone bradykinin and kallidin
(in humans) or kallidin-like peptide (in rodents).11 Binding
of bioactive bradykinin to B1R and/or B2R stimulates the
production of nitric oxide (NO) and prostaglandins, which
exerts protective effects on DN.12 Kwak et al.13 demonstrated
that by implanting an osmotic bradykinin minipump, urinary
albumin excretion in streptozotocin (STZ)-induced diabetic
rats was reduced, and podocyte apoptosis was also amelio-
rated. Overexpressing human tissue kallikrein has been shown
to prevent the development of DN in rats.8–10 However, the
mechanism through which kallikrein delayed the onset of
DN was unclear.
To illuminate whether exogenous supplement of pancre-
atic kallikrein (PKK) could protect DN and to explore the
mechanism, we used db/db mice, an obese type 2 diabetic1023
bas i c re sea r ch W Liu et al.: PKK protects against diabetic nephropathymouse, and STZ-induced type 1 diabetic mouse, as our
models. We showed that PKK treatment not only signiﬁcantly
prevented the development of DN when given at the onset of
diabetes, but also ameliorated DN when given after the onset
of albuminuria. PKK improved renal pathologic alterations,
which were accompanied by decreased renal ﬁbrosis,
inﬂammation, and oxidative stress product accumulation in
both types of diabetic mice. Moreover, PKK signiﬁcantly
increased the expression of kininogen 1, tissue kallikrein,
B1R, and B2R in diabetic mice. Our results suggest that the
renal protective effects of PKK are mediated, in part, through
the activation of KKS.
RESULTS
Animal characteristics
Data on body weight (BW), kidney weight (KW), blood
glucose (BG), blood pressure (BP), and lipid proﬁles for db/
db and db/m mice are summarized in Table 1. BG, BW, and
serum triglyceride levels of db/dbþsaline (db/dbþNS) and
db/dbþPKK groups were signiﬁcantly higher than in db/m
mice (P < 0.01), whereas the KW/BW ratio was lower than
db/m mice (P < 0.01). However, there was no difference
between db/dbþNS and db/dbþPKK groups. Other indexes
including systolic and diastolic BP, total cholesterol, high- and
low-density lipoprotein, showed no statistical differences
among all three groups. The characteristics of STZ-induced
diabetic mice was presented in Supplementary Table S1.
Noteworthy, compared with NDC group, the KW/BW ratio
was increased in STZþNS group (P<0.05), which was
reversed in STZþPKK group.
PKK decreased the urinary albumin/creatinine ratio in both
types 1 and 2 diabetic mice
Albuminuria is considered as an important indicator of
renal damage. Compared with db/m mice, db/dbþNS mice
showed a signiﬁcantly increased urinary albumin to creatinine
(Alb/Cre) ratio (Figure 1a), which was reduced by PKK.
In STZ-induced diabetic mice, PKK showed the same effect
(Figure 1b).Table 1 | Basic characteristics of mice
db/m (n [ 8) db/dbDNS (n [ 8)
BW (g) 24.25  3.06 42.64  4.76a
BG (mM) 5.43  0.64 27.37  4.63a
SBP (mm Hg) 115.75  8.25 110.20  8.8
DBP (mm Hg) 86.25  7.31 84  5.4
KW (mg) 307.8  18.83 380.5  13.52b
KW/BW (mg/g) 12.52  2.27 9.02  0.99a
TG (mM) 2.11  0.3 4.06  1.4c
TCH (mM) 4.50  0.63 5.31  1.44
HDL (mM) 2.19  0.25 2.68  0.71
LDL (mM) 1.76  0.62 1.53  0.56
BG, blood glucose; BW, body weight; DBP, diastolic blood pressure; HDL, high-density l
body weight; NS, saline; PKK, pancreatic kallikrein; SBP, systolic blood pressure; TCH, to
Data are mean  SEM.
aP < 0.001 versus db/m group.
bP < 0.01.
cP < 0.05.
1024PKK protected the kidney structure in DN
Previous studies demonstrated that the increase in glomerular
basement membrane (GBM) thickness was one of the most
important pathological changes in DN.14,15 To verify whether
PKK could protect the glomerulus of diabetic mice, we
examined the ultramicrostructure with transmission electron
microscopy (TEM). Our results showed that GBM thickness
was signiﬁcantly increased in the db/dbþNS group compared
with db/m mice, whereas PKK protected against this patho-
logic change (Figure 2a, red arrow). This was conﬁrmed by
semiquantitative analysis (Figure 2b). In addition, PKK also
protected the endothelial fenestrae from fusion or loss
(Figure 2c and d, yellow arrow), which partially explained the
protective role of PKK against albuminuria. Similar results
were observed in STZ-induced diabetic mice (Supplementary
Figure S1).
Hematoxylin and eosin, periodic acid–Schiff (PAS), and
Gomori trichrome reagent (Masson) staining were performed
to examine the pathologic changes. Hematoxylin and eosin
staining showed the inordinate arrangement of renal capillary
in db/dbþNS mice compared with db/m mice, whereas
exogenous PKK prevented this pathologic disorder (Figure 2e).
The percentages of PAS- or Masson-positive material, indica-
tive of mesangial expansion and collagen deposition, respec-
tively, and the glomerular sclerosis index were signiﬁcantly
increased in the diabetic glomeruli compared with db/m
controls (Figure 2f–i). However, both were signiﬁcantly atten-
uated in diabetic mice treated with PKK. Similar results for
PAS and Masson staining were also observed in STZ-induced
diabetic mice (Supplementary Figure S2).
PKK protected against the dysfunction and loss of podocytes
in DN
To verify whether PKK protected podocytes from injury and
dysfunction, we examined the ultrastructure of the foot
process with TEM and Wilms tumor (WT-1), a marker of a
podocyte, with immunohistochemistry (IHC), respectively.
Figure 3a shows that PKK protected against the effacement
of the foot process in diabetic mice (Figure 3a and c;db/dbDPKK (n [ 8) F value P value
42.64  4.76a 38.82 <0.001
26.90  3.04a 86.35 <0.0001
115.2  8.76 0.99 >0.05
84.4  4.92 0.62 >0.05
415.0  15.44b 11.7 <0.001
9.83  0.93b 7.27 <0.01
3.68  1.12c 6.88 <0.01
4.47  0.75 1.82 >0.05
1.99  0.31 4.94 >0.05
1.51  0.57 0.45 >0.05
ipoprotein; LDL, low-density lipoprotein; KW, kidney weight; KW/BW, kidney weight/
tal cholesterol; TG, triglyceride.
Kidney International (2016) 90, 1023–1036
Figure 1 | PKK decreased the urinary albumin to creatinine ratio in types 1 and 2 diabetic mice. (a,b) The urinary albumin to creatinine
ratio in types 1 and 2 diabetic mice. Data shown are mean  SEM. **P < 0.01 versus the db/m group; ##P < 0.01 versus the db/dbþNS group;
ffP < 0.01, fffP < 0.001 versus the NDC group; †††P < 0.001 versus the STZþNS group. NDC, nondiabetic control; NS, saline; PKK, pancreatic
kallikrein; STZ, streptozotocin.
W Liu et al.: PKK protects against diabetic nephropathy ba s i c re sea r chSupplementary Figure S1, blue arrow). The number of WT-1–
positive cells was signiﬁcantly reduced in the db/dbþNS
group compared with the db/m group, whereas PKK treat-
ment increased this number (Figure 3b and d).
Renal protective effects of PKK were associated with reduced
ﬁbrosis in DN
To verify whether PKK improved renal ﬁbrosis, we examined
renal ﬁbrosis with IHC. Compared with the db/m group,
db/dbþNS mice showed signiﬁcantly increased protein
expression of ﬁbronectin, collagen I, and TGF-b1 in both the
glomeruli and interstitial area, which were reduced in
db/dbþPKK mice (Figure 4a-f). We also found that the
mRNA expression of ﬁbronectin and protein expression of
collagen I was signiﬁcantly decreased by PKK treatment
(Figure 4h–i). Similar IHC results for collagen I and trans-
forming growth factor (TGF)-b1 in STZ-induced diabetic
mice are shown in Supplementary Figure S3.
Renal protective effects of PKK were associated with reduced
inﬂammation and oxidative stress
CD68 is a marker of macrophages, which reﬂect inﬂamma-
tion. We found that CD68 expression was increased in
db/dbþNS mice compared with db/m mice. However, it was
decreased in db/dbþPKK mice (Figure 5a and c). In addition,
the gene expression of interleukin-1b, an important cytokine
in mediating renal inﬂammation, was elevated in db/dbþNS
mice compared with db/m mice. Notably, PKK also decreased
the expression of interleukin-1b (Figure 5d). These results
suggested that PKK exerted anti-inﬂammatory effects in
diabetic kidneys.
Biomarkers including nitrotyrosine and glutathione (GSH)
were detected to assess oxidative stress. Compared with db/m
group, there was a signiﬁcant accumulation of nitrotyrosine,
a marker of oxidized protein, in the renal cortex of the
db/dbþNS group, which was reduced by PKK (Figure 5b and
f). Furthermore, we found that PKK increased renal GSH, a
major component of the antioxidative system, compared with
saline (P < 0.05) (Figure 5e).Kidney International (2016) 90, 1023–1036PKK activated the expression of the KKS in diabetic mice
The gene and protein expressions of renal KKS components
are shown in Figure 6. Compared with db/m mice, db/dbþNS
mice showed a trend of increased mRNA levels of kininogen
1, kallikrein, B1R, and B2R, but this trend did not reach
statistical signiﬁcance (Figure 6a–d). However, the PKK
treatment signiﬁcantly increased mRNA expression. We also
examined the protein expression of B2R in the kidneys of
both types of diabetic mice (Figure 6i–k). Compared with
db/m mice, the expression of B2R in the db/dbþNS group
was not statistically different, whereas PKK signiﬁcantly
increased B2R protein expression. In addition, the mRNA
levels of these 4 genes and renal bradykinin concentration
were all increased in the STZþPKK group compared with the
STZþNS group (Figure 6e–h; Supplementary Figure S4).
PKK treatment reduced the Alb/Cre ratio and serum creati-
nine levels when given after the onset of albuminuria
In order to test whether PKK is capable of reversing DN, we
treated the STZ-induced diabetic mice with PKK for 8 weeks
after the onset of albuminuria. Data on body weight (BW),
KW, BG, and BP for these mice are summarized in
Supplementary Table S2. As shown in Figure 7a, after 8 weeks
of of diabetes, the Alb/Cre ratio was signiﬁcantly increased in
STZ00 mice compared with nondiabetic control (NDC)00 mice
(the prime symbols indicate that these mice are relevance to
the period before the PKK or saline treatment). However,
after another 8 weeks of PKK treatment, the increased
Alb/Cre ratio was reversed. Moreover, the serum creatinine
level was also decreased in the STZ0þPKK group compared
with the STZ0þNS group (Figure 7b).
PKK protected the kidney structure when given after the
onset of albuminuria in STZ-induced diabetic mice
As shown, GBM thickness was signiﬁcantly increased in
the STZ0þNS group compared with NDC0 mice, whereas
PKK ameliorated this pathologic change (Figure 8a, red
arrow). In addition, PKK also improved the fusion or loss of
endothelial fenestrae (Figure 8a, yellow arrow) and reversed1025
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Figure 2 | PKK protected the kidney structure in diabetic nephropathy. (a,c) Representative electronic micrographs of the GBM and
fenestrae of endothelial cells, respectively. In db/m mice, normal basement membrane and regular fenestrae of endothelial cells were observed.
Basement membrane thickening and extensive fusion of fenestrae of endothelial cells were observed in the db/dbþNS group. However, the
thickness of the basement membrane in the db/dbþPKK group was signiﬁcantly reduced compared with the db/dbþNS group. The fenestrae
of endothelial cells were improved in db/dbþPKK mice. (b,d) The quantitative thickness of the GBM and endothelial fenestrations for these 3
groups. Red and yellow arrows point to the GBM and fenestrae of endothelial cells, respectively. (e,f,h) Morphometric analysis of the PAS- or
Masson-positive area was performed in renal sections of all mice. Representative images of kidney tissue stained with HE, PAS, and Masson for
the db/m, db/dbþNS, and db/dbþPKK groups are presented (original magniﬁcation 40). (g,i) The glomerular sclerosis indexes for PAS and
Masson staining, respectively. Data shown are mean  SEM. *P < 0.05, **P < 0.01, ***P < 0.001 versus the db/m group; #P < 0.05, ###P < 0.001
versus the db/dbþNS group. GBM, glomerular basement membrane; GBMT, glomerular basement membrane thickness; HE, hematoxylin and
eosin; NS, saline; PAS, periodic acid–Schiff; PKK, pancreatic kallikrein.
bas i c re sea r ch W Liu et al.: PKK protects against diabetic nephropathythe effacement of the foot process in diabetic mice compared
with STZ0þNS mice (Figure 8a, blue arrow). Semiquantitative
analysis further conﬁrmed our ﬁndings (Figure 8b–d).
Moreover, PAS and Masson staining showed that PKK treat-
ment restored normal kidney histologic architecture and
decreased renal ﬁbrosis (Figure 8e–h).
PKK restored podocyte number, reduced renal ﬁbrosis and
inﬂammation, and increased urinary NO level when given
after the onset of albuminuria
Further, we performed WT-1, collagen I, TGF-b1, and CD68
IHC staining, which showed that PKK restored the number
of podocytes (Figure 9a and b), which was consistent with
the TEM results. The antiﬁbrotic effects of PKK, which were1026veriﬁed by collagen I IHC staining (Figure 9c and d), were
accompanied by decreased TGF-b1 and CD68 protein
expression (Figure 9e-h). In addition, we tested the urinary
nitrate levels, which reﬂected the NO levels. Although
without reaching statistical signiﬁcance, the NO level tended
to be decreased in STZ0þNS mice compared with NDC0 mice
(Supplementary Figure S5) (P ¼ 0.0874), whereas this ten-
dency was partially reversed by PKK (P ¼ 0.0776). We also
tested the expression of renal KKS by detecting the mRNA
expression of kininogen 1, kallikrein, B1R, and B2R
(Figure 9i-l). Similarly, PKK treatment signiﬁcantly increased
mRNA expression on these 4 genes compared with the other
2 groups, indicating that KKS activation might partially
mediate the protective effect of PKK on DN.Kidney International (2016) 90, 1023–1036
Figure 3 | PKK protected against the dysfunction and loss of podocytes in DN. (a) The electron microscope images of the foot processes of
the podocyte. In db/dbþNS mice, signiﬁcant effacement of the foot processes was observed, which was improved in the db/dbþPKK group. (b)
The WT-1–positive podocytes in each glomerulus. (c,d) The quantiﬁcation results of the foot process width and the number of WT-1–positive
cells per glomerulus, respectively. Data shown are mean  SEM. *P < 0.05, ***P < 0.001 versus the db/m group, #P < 0.05, ###P < 0.001 versus
the db/dbþNS group. DN, diabetic nephropathy; NS, saline; PKK, pancreatic kallikrein; WT-1, Wilms tumor.
W Liu et al.: PKK protects against diabetic nephropathy ba s i c re sea r chDISCUSSION
The KKS was recognized at the discovery that urine contains a
vasodilator substance further identiﬁed in pancreatic extracts
and named kallikrein in 1930.16,17 It is now well established
that the KKS is a complex enzymatic system and expressed
ubiquitously in many organs, including kininogen, serum or
tissue kallikreins and other serine proteases, kinins and their
derivatives (Supplementary Figure S6).4,18 Emerging evidence
suggests a protective role for the KKS in the pathogenesis of
DN. B2R knockout Akita mice and STZ-induced tissue
kallikrein knockout diabetic mice displayed more severe
albuminuria and glomerulosclerosis.7,19 Moreover, previous
studies demonstrated that bradykinin, the major mediator of
the KKS, inhibited high glucose- and growth factor–inducedKidney International (2016) 90, 1023–1036collagen synthesis in mesangial cells of diabetic mice.20
Exogenous supply of KKS activators such as kinin, human
tissue kallikrein cDNA (rAAV-HK), and B2R agonist effec-
tively improved DN in diabetic models.8,21,22
In the current study, we treated type 1 and 2 diabetic mice
with PKK and found that it not only protected against the
development of DN, but also ameliorated DN when given
after the onset of albuminuria. Our results demonstrated that
exogenous PKK decreased the Alb/Cre ratio, ameliorated
renal pathologic changes including a thickened GBM,
effacement of foot processes, and loss of endothelial fenestrae.
We also evaluated the ﬁbrosis, inﬂammation, and oxidative
stress as they are the most important pathways in the devel-
opment of DN.23–28 We found that exogenous PKK reduced1027
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Figure 4 | Renal protective effects of PKK were associated with reduced ﬁbrosis in diabetic kidneys. (a,c,e) Representative
immunohistochemical micrographs of kidney tissue stained with ﬁbronectin, collagen I, and TGF-b1 for the db/m, db/dbþNS, and db/dbþPKK
groups. Original magniﬁcation 40. (b,d,f) The immunohistochemical scores of kidney sections for ﬁbronectin, collagen I, and TGF-b
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ﬁbronectin for these 3 groups. Data shown are mean  SEM. *P < 0.05, **P < 0.01 versus the db/m group; #P < 0.05, ##P < 0.01 versus the
db/dbþNS group. NS, saline; PKK, pancreatic kallikrein; TGF-b, transforming growth factor-b.
bas i c re sea r ch W Liu et al.: PKK protects against diabetic nephropathyand reversed these pathologic pathways, suggesting that PKK
has renal protective effects in diabetic mice.
After conﬁrming the renal protective effect of exogenous
PKK, we explored the underlying mechanism. Because the
increased substrate (kininogen) or enzyme (tissue kallikrein)
could result in producing more bradykinin and NO, which
were the major mediators of KKS, we examined the expres-
sion of every component of KKS in our animals. We found
that PKK treatment increased the gene expression of tissue
kininogen 1, kallikrein 1, B1R and B2R and protein expres-
sion of B2R. Moreover, we found that PKK could increase the
renal bradykinin level in STZ-induced diabetic mice, which
may partially explain the protective role of PKK in DN.
Previous studies demonstrated that the gene expression of
KKS, including tissue kallikrein, kininogen, B1R, and B2R, was
increased in the kidney of 3-month-old C57Bl/6J db/db
mice.19,29,30 However, in ourmousemodels, gene expression of
KKS in the kidney was not statistically different from that in
NDC mice. This discrepancy may be due, at least in part, to1028differences in genetic background, severity of hyperglycemia,
and duration of diabetes. Interestingly, our results suggest a
“positive feedback” mechanism in the KKS in our mouse
models. In diabetic mice treated with PKK, the expression
of both B1R and B2R were signiﬁcantly increased, which
implies the upregulation of both receptors by the elevated
bradykinin level. Previous studies demonstrated that the
main regulatory mechanism of bradykinin receptor expression
was at the transcriptional and posttranscriptional levels. In
trauma, acute inﬂammation, and stress, upregulation of B1R
and B2R occurred under the control of some cytokines,
including interleukin-1b, TNF-a, and lipopolysaccharide.31–34
Previous studies by Saifudeen et al.35 suggested an important
role of p53 in upregulating the G protein–coupled receptor
B2R during kidney development in mice. Speciﬁcally,
p53-induced B2R activation was mediated by the direct
binding to the promoter region of the BK2 gene.35 Further-
more, the combined interactions among transcriptional
factors or coactivators including p53, CREB, KLF-4, and CBPKidney International (2016) 90, 1023–1036
Figure 5 | Renal protective effects of PKK were associated with reduced inﬂammation and oxidative stress in diabetic kidneys. (a,b)
Representative IHC micrographs of kidney tissue stained with CD68 and nitrotyrosine for the db/m, db/dbþNS, and db/dbþPKK groups,
respectively. Original magniﬁcation 40. (c) The IHC scores of kidney sections for CD68 IHC staining. (d) The gene expression of IL-1b for these 3
groups. (e) The IHC scores of kidney sections for nitrotyrosine IHC staining. (f) GSH level for these 3 groups. Data shown are mean  SEM.
*P < 0.05, **P < 0.01 versus the db/m group; #P < 0.05, ##P < 0.01 versus the db/dbþNS group. GSH, glomerular stimulating hormone; IHC,
immunohistochemistry; IL-1b, interleukin-b; NS, saline; PKK, pancreatic kallikrein.
W Liu et al.: PKK protects against diabetic nephropathy ba s i c re sea r chappeared to be critical in the regulation of B2R gene expres-
sion, particularly during terminal nephron differentiation.35
In cultured rat aortic vascular smooth muscle cells, YanKidney International (2016) 90, 1023–1036et al.36 found that bradykinin could upregulate the expression
of B2R through mitogen-activated protein kinase and phos-
phatidylinositol-30-kinase/Akt signaling pathways.With regard1029
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Figure 6 | PKK activated the expression of the kallikrein-kinin system genes. (a–h) The RQ values of kininogen 1, kallikrein 1, B1R, and B2R
are shown. (i) The protein expression of B2R tested by Western blot. (j,k) The semiquantitative results demonstrated in (i). Data shown are mean
 SEM. *P < 0.05, **P < 0.01, ***P < 0.001 versus db/m group; #P < 0.05, ##P < 0.01, ###P < 0.001 versus the db/dbþNS group; fP < 0.05,
ffP < 0.01 versus the NDC group; †P < 0.05, ††P <0.01 versus the STZþNS group. B1R, bradykinin receptor type I; B2R, bradykinin receptor type
II; NDC, nondiabetic control; NS, saline; PKK, pancreatic kallikrein; RQ, relative quantity; STZ, streptozotocin; WT, Wilms tumor.
bas i c re sea r ch W Liu et al.: PKK protects against diabetic nephropathyto DN, Bodin et al.19 found that B1R and B2R gene expression
was increased by diabetes in bothWTand tissue kallikrein-null
mice, so they ruled out the possibility of ligand-induced
receptor upregulation. However, they did not explore the
potential mechanism further. In our mouse model, the
gene expression of B1R and B2Rwas not signiﬁcantly increased
in diabetic mice compared with NDC mice. Nevertheless,1030exogenous PKK signiﬁcantly increased gene expression of both
receptors, which indicated that this upregulation might be
mediated by ligand-induced effects.
Interestingly, a recent paper demonstrated that kallistatin,
which could inhibit endogenous tissue kallikrein activity,
had a renoprotective effect on DN.37 The discrepancy
between this research and ours may be due to differentKidney International (2016) 90, 1023–1036
Figure 7 | PKK treatment reduced the urinary albuminuria-to-creatinine ratio and serum creatinine levels when given after the onset of
albuminuria in STZ-induced diabetic mice. (a) The urinary albumin-to-creatinine ratio in STZ-induced type 1 diabetic mice with 8-week
duration of diabetes (STZ0 0 groups) and 16 weeks’ duration of diabetes (STZ0þNS group and STZ0þPKK group). At 8 weeks after the onset of
diabetes, the STZ0 0 group developed signiﬁcant albuminuria compared with NDC0 0 group. After conﬁrming the presence of albuminuria, PKK or
saline was given for another 8 weeks. Compared with the STZ0þNS group, the STZ0þPKK group showed decreased urinary albuminuria.
(b) The serum creatinine levels in STZ-induced type 1 diabetic mice. Data shown are mean  SEM. &P < 0.05 versus the NDC0 0 group; þþP < 0.01,
þþþP < 0.001 versus the NDC0 group; s¸P < 0.05 versus the STZ0þNS group. NDC, nondiabetic control; NS, saline; PKK, pancreatic kallikrein;
STZ, streptozotocin. STZ0 0 and NDC0 0 refer to the pre-PKK or saline treatment period.
W Liu et al.: PKK protects against diabetic nephropathy ba s i c re sea r chmodels. In the study by Yiu et al.,37 kallistatin overexpression
was genetically induced speciﬁcally in renal tubules by
ultrasound microbubble–mediated gene transfer, whereas in
our study, PKK was systemically administered, which might
lead to broader effects. Yiu et al.37 concluded that the reno-
protective effect of kallistatin was due to the reduced oxidative
stress and systolic blood pressure. However, in our models,
PKK decreased oxidative stress, but had no effects on blood
pressure. Moreover, previous studies showed that tissue
kallikrein improved insulin resistance8,9 and metabolic pro-
ﬁles,10 which might contribute the renal protection. In our
study, PKK-treated mice showed a decreasing trend of plasma
total cholesterol and triglycerides, which might partially
mediate the protective effects.
Our ﬁndings showed that PKK treatment improved DN in
diabetic mice through the regulation of KKS, mediated at least
in part by activation of B1R and B2R. Further studies are
warranted to examine the mechanism of a protective role of
PKK in DN.
In summary, we found that exogenous PKK has renal
protective effects in type 1 and 2 diabetic mice, exempliﬁed by
the improvement of pathologic structures, reduced protein-
uria, glomerulosclerosis, renal inﬂammation, and oxidative
stress. Thus, exogenous PKK could be an effective medication
to protect against DN.
MATERIALS AND METHODS
Animal study
All animal studies were performed in accordance with approved
Institutional Animal Care and Use Committee protocols at Fudan
University. Sixteen male C57BLKS/J db/db mice (obtained from the
Model Animal Research Center, MARC, Nanjing University, Nanjing,
China) weighing 22 to 26 g were injected either with saline (n ¼ 8,
0.1 ml/10 g, db/dbþNS group) or PKK intraperitoneally (Qianhong
Bio-pharma Company, Changzhou, China) (n ¼ 8, 60 U/kg1 per
day, db/dbþPKK group) for 16 weeks. In addition, littermate db/m
mice (n ¼ 8, db/m group) were given saline (0.1 ml/10 g) as theKidney International (2016) 90, 1023–1036NDC group. For the type 1 diabetic mouse model, 5-week-old male
DBA mice (obtained from Shanghai Laboratory Animal Center,
Shanghai, China) were made diabetic as described previously.38
Brieﬂy, mice were injected with STZ (50 mg/kg, i.p.) on 5 consec-
utive days. After the onset of diabetes, determined by hyperglycemia
as BG reached 16.7 mmol/l at 1 week post-injection, mice were
separated into either a PKK-treated group (n ¼ 8, STZþPKK group)
or a control group treated with saline (n ¼ 8, STZþNS group). After
12 weeks of treatment, the mice were killed. For another group of
STZ-induced mice (n ¼ 12, designed as the STZ0 0 group), we
measured the Alb/Cre ratio at 8 weeks after the onset of diabetes and
signiﬁcant albuminuria had developed compared with the corre-
sponding control NDC0 0 group. Then these mice received either PKK
(n ¼ 6, designed as the STZ0þPKK group) or saline (n ¼ 6, designed
as the STZ0þNS group) for another 8 weeks. The NDC0 group
(n ¼ 6) received saline. Mice were housed in a temperature-
controlled room and given free access to water and standard labo-
ratory chow during the whole study period.
BW and BG were checked weekly, and KW was measured when
the mice were killed. BP was measured monthly by tail-cuff phle-
thysmography (BP-98A, Softron Beijing Incorporated, Beijing,
China). Mice were housed in metabolic cages, and 24-hour urine
samples were collected. The urinary albumin level was measured by
enzyme-linked immunosorbent assay (Bethyl Laboratory Inc.,
Houston, TX, USA). Urinary creatinine concentration was deter-
mined using a chemiluminescence assay (Exocell, Philadelphia, PA,
USA), and Alb/Cre ratio was calculated.
Histologic evaluation
Partial cortexes of kidneys were ﬁxed with 4% paraformaldehyde
overnight. Tissues were embedded in parafﬁn, stained with he-
matoxylin and eosin or PAS or with Masson reagent, and examined
under an optical microscope. The glomerular sclerosis index was
calculated as previously described.39 Renal tissue was also examined
with TEM after ﬁxation with 10% glutaraldehyde. The GBM
thicknesses in TEM pictures were measured by ImageJ soft-
ware.40,41 The method to measure the width of the foot process
was previously described in detailed.42 Foot process effacement is
determined as the length of the effacement divided by the length of1031
Figure 8 | PKK protected the kidney structure when given after the onset of albuminuria in STZ-induced diabetic mice. (a) The
representative electronic micrographs for the glomerular ﬁltration barrier in STZ-induced diabetic mice that were treated after the (Continued)
bas i c re sea r ch W Liu et al.: PKK protects against diabetic nephropathy
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Figure 9 | PKK restored podocyte number, reduced renal ﬁbrosis and inﬂammation, and activated the expression of the kallikrein-kinin
system when given after the onset of albuminuria. (a,c,e,g) Representative immunohistochemical micrographs of kidney tissue stained with
WT-1, collagen I, TGF-b1, and CD68 for NDC0, STZþNS0, and STZþPKK0 groups. Original magniﬁcation 40. (b,d,f,h) The immunohistochemical
scores for WT-1, collagen I, TGF-b1, and CD68 IHC staining, respectively. (i–l) The RQ values of kininogen1, kallikrein 1, B1R, and B2R. Data shown
are mean  SEM. þP < 0.05, þþP < 0.01, þþþP < 0.001 vs. the NDC0 group, s¸P < 0.05, s¸s¸P < 0.01, s¸s¸s¸P < 0.001 vs. the STZ0 þ NS group. B1R,
bradykinin receptor type I; B2R, bradykinin receptor type II; NDC, nondiabetic control; NS, saline; PKK, pancreatic kallikrein; RQ, relative quantity;
STZ, streptozotocin; TGF-b1, transforming growth factor b1; WT-1, Wilms tumor. STZ0 0 and NDC0 0 refer to the pre-PKK or saline treatment period.
W Liu et al.: PKK protects against diabetic nephropathy ba s i c re sea r chthe capillary. Five glomeruli per mouse and 5 open random
capillary loops per glomerulus for 3 mice in each experimental
group were also measured by using ImageJ. As to the quantiﬁcationFigure 8 | (Continued) onset of albuminuria. (b–d) The quantitative thickn
groups. Red, blue, and yellow arrows point to the GBM, foot process, and
of PAS and Masson staining for the NDC0, STZþNS0, and STZþPKK0 group
for PAS and Masson staining, respectively. Data shown are mean  SEM
the STZ0þNS group. GBM, glomerular basement membrane; GBMT, glom
NS, saline; PAS, periodic acid–Schiff; PKK, pancreatic kallikrein; STZ, strepto
to the pre-PKK or saline treatment period.
Kidney International (2016) 90, 1023–1036of endothelial fenestrations, values are expressed as mean number
of endothelial fenestrations per 100 mm of capillary loop
perimeter.43ess of the GBM, foot process, and endothelial fenestrations for these 3
fenestrae of endothelial cells, respectively. (e,f) Representative images
s (original magniﬁcation 40). (g,h) The glomerular sclerosis indexes
. þþP < 0.01, þþþP < 0.001 versus the NDC0 group, s¸s¸s¸P < 0.001 versus
erular basement membrane thickness; NDC, nondiabetic control;
zotocin; TEM, transmission electron microscopy. STZ0 0 and NDC0 0 refer
1033
Table 2 | Sequences of primers used for real-time PCR
Forward Reverse
IL-1b 50-GAAATGCCACCTTTTGACAGTG-30 50-TGGATGCTCTCATCAGGACAG-30
Fibronectin 50-TCCCGGGCAGAAAGTACATT-30 50-TTCAGGGAGGTTGAGCTCTG-30
Kininogen 1 50-CCGGACTCCTGCTGACTTTA-30 50-CATCCGTTTTAGTGCCCTCG-30
Kallikrein 1 50-GCAGCATTACACCCGTCAAA-30 50-AGTGTCTTTGCCTCCATCCA-30
B1R 50-GCCAGGGTTTGTCATCACTG-30 50-CCCAGCACAAACACCAGATC-30
B2R 50-TCGTGAGTATCGACCGCTAC-30 50-CCCTCTTCGCTGTATTCCCT-30
b-Actin 50-GAGACCTTCAACACCCCAGC-30 50-ATGTCACGCACGATTTCCC-30
ACE, angiotensin-converting enzyme; B1R, type I bradykinin receptor; B2R, type II bradykinin receptor; IL-1b, interleukin-1b; PCR, polymerase chain reaction.
bas i c re sea r ch W Liu et al.: PKK protects against diabetic nephropathyImmunohistochemistry
Expression of WT-1 (sc-192, Santa Cruz Biotechnology Inc., Dallas,
TX, USA), TGF-b1 (sc-146, Santa Cruz Biotechnology Inc.), ﬁbro-
nectin (ab2413, Abcam, Cambridge, MA, USA), collagen I (ab34710,
Abcam), CD68 (MCA1957-GA, AbD Serotec Company, AbD Sero-
tec, Kidlington, UK), and nitrotyrosine (2459610, Millipore, Bill-
erica, MA, USA) was examined on parafﬁn-embedded renal tissue
sections (5 mm) by IHC analysis, as described previously. The
dilution was 1:100, 1:100, 1:100, 1:200, 1:100, and 1:200, respectively.
Analysis of WT-1 and CD68 staining and the number of positively
stained cells per glomerular cross-section area in the kidney sections
was performed, as described previously.44 For other antibodies, each
section was captured for at least 10 images, and all these images were
quantiﬁed by Image Pro Plus 6.0 software (Media Cybernetics, Silver
Spring, MD, USA). Data were expressed as the ratio of integrated
optical density to area.
RNA extraction and real-time polymerase chain reaction
Kidneys from control and diabetic mice were collected after killing,
and cortexes were isolated to extract RNA using Trizol (Invitrogen,
Carlsbad, CA, USA) followed by the manufacturer’s instructions.
Total RNA was dissolved in the ethylenediamine tetraacetic acid–free
water. The RNA concentration was determined with a spectropho-
tometer (Nanodrop 2000c, Thermo Fisher Scientiﬁc, Waltham, MA,
USA) by absorbance at 260 nm. According to the manufacturer’s
protocols, RNA (2 mg) was converted to cDNA (G490, Abm Canada,
Milton, Ontario, Canada) and then reverse transcriptase–polymerase
chain reaction was conducted on ABI 7500 (Applied Biosystems,
Foster City, CA, USA) with SYBR Green PCR Master Mix (Applied
Biosystems). The primers used in this paper are shown in Table 2.
Each sample was run in triplicate to permit precise quantiﬁcation of
the gene normalized to the b-actin gene.
Measurement of renal GSH, renal bradykinin, and urinary
nitrate levels
Renal GSH, bradykinin, and nitrate levels were determined with a
spectrophotometric method according to the manufacturer’s in-
structions (703002, Cayman Chemical Companys, Ann Arbor, MI,
USA; EK-009-01, Phoenix Pharmaceuticals, Burlingame, CA, USA;
780001, Cayman Chemicals). The results for GSH and bradykinin
were standardized to homogenate protein levels.
Protein extraction and Western blot analysis
The renal cortex of the kidney was homogenized in an ice-cold lysis
buffer containing 150 mmol/l NaCl, 50 mmol/l Tris-HCl (pH 8.0),
0.1% sodium dodecylsulfate, 1% Nonidet P-40, and protease
inhibitor cocktail (Roche Applied Science, Mannheim, Germany).
These samples were resolved by 10% sodium dodecylsulfate–
polyacrylamide gel electrophoresis and transferred to polyvinylidene1034diﬂuoride membranes (Millipore). The membranes were incubated
with rabbit anti-collagen I antibody (1:5000), rabbit anti-B2R anti-
body (1:2000), and rabbit anti–b-actin antibody (1:5000),
washed and incubated with goat anti-rabbit peroxidase–coupled
secondary antibodies (1:10,000). The blots were visualized by an
enhanced chemiluminescence detection system (PerkinElmer,
Boston, MA, USA).45
Statistical analysis
All data were expressed as mean  SEM from 3 independent
experiments. Statistical analysis was performed using the statistical
package SPSS for Mac Version 20.0 (SPSS, Inc., Chicago, IL, USA).
The signiﬁcance of the differences in mean values among different
groups was evaluated using 1-way analysis of variance followed by
the Tukey test. P values <0.05 were considered to be statistically
signiﬁcant.
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SUPPLEMENTARY MATERIAL
Figure S1. PKK protected the ultrastructure of glomerular ﬁltration
barrier in STZ-induced diabetic mice. (A) The representative electronic
micrographs for glomerular ﬁltration barrier in STZ-induced diabetic
mice. (B–D) The quantitative thickness of GBM, foot process, and
endothelial fenestrations for these three groups. Red, blue, and yel-
low arrows point to GBM, foot process, and fenestrae of endothelial
cells, respectively. Data are means  SEM. ffP < 0.01, fffP < 0.001
versus NDC group; yyP < 0.01, yyyP < 0.001 versus STZþNS group.
Figure S2. PKK reduced glomerular mesangial expansion and
collagen deposition in STZ-induce diabetic mice. (A,C) Representative
images of PAS and Masson staining for NDC, STZþNS and STZþPKK
groups (original magniﬁcation 40). (B) The glomerular sclerosis in-
dexes for PAS and Masson staining, respectively. Data are means 
SEM. fffP < 0.001 versus NDC group; yyP < 0.01, yyyP < 0.001 versus
STZþNS group.
Figure S3. Renal protective effects of PKK were associated with
reduced ﬁbrosis and inﬂammation in STZ-induced diabetic kidneys.
(A,C,E) Representative immunohistochemical micrographs pictures
of kidney tissue stained with collagen I, TGF-b1, and CD68 for NDC,
STZþNS, and STZþPKK groups. Original magniﬁcation 40. (B,D,F)
The immunohistochemical scores for these 3 IHC stainingKidney International (2016) 90, 1023–1036
W Liu et al.: PKK protects against diabetic nephropathy ba s i c re sea r chrespectively. Data are means  SEM. ffP < 0.01, fffP < 0.001 versus
NDC group; yyP < 0.01, yyyP < 0.001 versus STZþNS group.
Figure S4. PKK treatment tended to increase the renal bradykinin
level in STZ-induced diabetic mice. The renal bradykinin level in NDC,
STZþNS, and STZþPKK groups. Data are means  SEM. fP < 0.05
versus NDC group; yP < 0.05 versus STZþNS group.
Figure S5. PKK likely increased urinary nitrate levels in diabetic mice.
The urinary nitrate level in NDC’, STZþNS’, and STZþPKK’ groups.
Data are means  SEM.
Figure S6. Renal kallikrein-kinin system (KKS) and renin-angiotensin-
aldosterone system (RASS). The components and molecular
interaction between renal kallikrein-kinin system and renin-
angiotensin-aldosterone system. Bradykinin, kallidin (humans),
and kallidin-like peptide (rodents) are generated from kininogens
by kallikreins. By activating bradykinin receptors (type 1 and
type 2, B1R and B2R), all kinins could stimulate two intracellular
signaling pathways, phospholipase A2 (PLA2)-dependent and
phosphatidylinositol-speciﬁc phospholipase C (PI-PLC)-dependent
pathways. This activation could result in the production of nitric oxide
(NO) and prostaglandins (PGs), which may further perform the renal
protective roles in DN. Kallikrein could also convert pro-renin into
renin, which further catalyze angiotensinogen into angiotensin I.
Importantly, kinins could be degraded into inactive forms by kininase II
(ACE), while angiotensin I could be transformed into angiotensin II.
LMWK, low molecular weight kininogen; HMWK, high molecular
weight kininogen; Gq, Gq protein; Gi, Gi protein; iNOS, inducible nitric
oxide synthase; eNOS, endothelial nitric oxide synthase; ER, endo-
plasmic reticulum; PRCP, lysosomal pro-X carboxypeptidase; AT1R,
type 1 angiotensin receptor; AT2R, type 2 angiotensin receptor;
AT(1-7)R, angiotensin receptor for angiotensin II (1-7). Adapted with
permission from Tomita H, Sanford RB, Smithies O, et al. The kallikrein-
kinin system in diabetic nephropathy. Kidney Int. 2012;81:733–744.4
Table S1. Basic characteristics of DBA mice treated for 12 weeks.
Table S2. Basic characteristics of mice.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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